Homepage > Company > Media > Pharma News > 2025 > iBio to Present New Preclinical Data

iBio to Present New Preclinical Data

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

SAN DIEGO, Oct. 21, 2025 -- iBio, Inc., an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta.

In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon.

Obesity Week Presentation Details:
Title: Discovery and Testing of a First-in-Class Activin E Antagonist Antibody for the Treatment of Obesity. Date: November 4, 2025, Presenter: Cory Schwartz, Director of Research and Early Development, iBio.
Dr. Schwartz will also present a poster titled “Preclinical Evaluation of a Long-Acting Anti-Myostatin Therapy for Obesity” on November 5 at 2:30 p.m. EST

Title: A First-in-Class Anti-Activin E Antibody Induces Fat-Selective Weight-Loss in Diet-Induced Obese Mice. Date: November 12, 2025, Presenter: Martin Brenner, CEO and CSO, iBio.

“We are excited to share additional data from the non-human primates study of our Activin E antibody, IBIO-610, which continues to support its potential as a differentiated approach to the treatment of obesity,” said Dr. Brenner. “These findings add to a growing body of research that inhibiting Activin E signaling could deliver fat-selective weight loss, support long-term weight maintenance, and enhance the benefits of GLP-1 therapies. These data suggest IBIO-610 could help overcome key limitations of current therapies and advance the next generation of cardiometabolic therapies.”

iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...